Page 816 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPtEr 57 Spondyloarthritis 787

35. Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and 43. Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral
cerebrovascular diseases in individuals with ankylosing spondylitis: a phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and
population-based study. Arthritis Rheum 2011;63:3294–304. current skin involvement: a phase III, randomised, controlled trial
36. Sairanen E, Paronen I, Mahonen H. Reiter’s syndrome: a follow-up study. (PALACE 3). Ann Rheum Dis 2016;75:1065–73.
Acta Med Scand 1969;185:57–63. 44. Barber CE, Kim J, Inman RD, et al. Antibiotics for treatment of reactive
37. Gladman DD, Chandran V. Review of clinical registries of psoriatic arthritis: a systematic review and meta-analysis. J Rheumatol
arthritis: lessons learned?: value for the future? Curr Rheumatol Rep 2013;40:916–28.
2011;13:346–52. 45. Coates LC, Helliwell PS. Treating to target in psoriatic arthritis: how to
38. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/ implement in clinical practice. Ann Rheum Dis 2016;75:640–3.
Spondylitis Association of America/Spondyloarthritis Research and 46. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the
Treatment Network 2015 Recommendations for the Treatment of treatment of axial spondylarthritis without radiographically defined
Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. sacroiliitis: results of a twelve-week randomized, double-blind,
Arthritis Rheumatol 2016;68:282–98. placebo-controlled trial followed by an open-label extension up to week
39. van den Berg R, Baraliakos X, Braun J, et al. First update of the current fifty two. Arthritis Rheum 2008;58:1981–91.
evidence for the management of ankylosing spondylitis with 47. Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on
non-pharmacological treatment and non-biologic drugs: a systematic signs and symptoms of axial spondyloarthritis including ankylosing
literature review for the ASAS/EULAR management recommendations in spondylitis: 24-week results of a double-blind randomised
ankylosing spondylitis. Rheumatology (Oxford) 2012;51:1388–96. placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73:
40. Wanders A, van der Heijde D, Landewe R, et al. Nonsteroidal 39–47.
anti-inflammatory drugs reduce radiographic progression in patients 48. Haroon N, Inman RD, Learch TJ, et al. The Impact of TNF-inhibitors on
with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum radiographic progression in Ankylosing Spondylitis. Arthritis Rheum
2005;52:1756–61. 2013;65:2645–54.
41. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal 49. Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin-17A
anti-inflammatory drugs on radiographic spinal progression in patients Inhibitor, in Ankylosing Spondylitis. N Engl J Med 2015;373:
with axial spondyloarthritis: results from the German Spondyloarthritis 2534–48.
Inception Cohort. Ann Rheum Dis 2012;71:1616–22. 50. Van Royen BJ, De Gast A. Lumbar osteotomy for correction of
42. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and thoracolumbar kyphotic deformity in ankylosing spondylitis. A
placebo for the treatment of axial and peripheral articular manifestations structured review of three methods of treatment. Ann Rheum Dis
of the seronegative spondylarthropathies: a Department of Veterans 1999;58:399–406.
Affairs cooperative study. Arthritis Rheum 1999;42:2325–9.